Literature DB >> 25887068

Hemostatic Factors, APOL1, and ESRD Risk: Another Piece of the Puzzle?

Walter G Wasser1, Etty Kruzel-Davila2.   

Abstract

Entities:  

Keywords:  CKD; FSGS; HIV nephropathy; endothelium

Mesh：

Substances：

Year:  2015        PMID： 25887068      PMCID： PMC4422231          DOI： 10.2215/CJN.03220315

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  26 in total

1.  sPLA2-V inhibits EPCR anticoagulant and antiapoptotic properties by accommodating lysophosphatidylcholine or PAF in the hydrophobic groove.

Authors:  Jacinto López-Sagaseta; Cristina Puy; Ibai Tamayo; Mikel Allende; Jorge Cerveró; Susana E Velasco; Charles T Esmon; Ramón Montes; José Hermida
Journal:  Blood       Date:  2011-12-13       Impact factor: 22.113

Review 2.  Bidirectional relation between inflammation and coagulation.

Authors:  Marcel Levi; Tom van der Poll; Harry R Büller
Journal:  Circulation       Date:  2004-06-08       Impact factor: 29.690

3.  Association of trypanolytic ApoL1 variants with kidney disease in African Americans.

Authors:  Giulio Genovese; David J Friedman; Michael D Ross; Laurence Lecordier; Pierrick Uzureau; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Taras K Oleksyk; Andrea L Uscinski Knob; Andrea J Bernhardy; Pamela J Hicks; George W Nelson; Benoit Vanhollebeke; Cheryl A Winkler; Jeffrey B Kopp; Etienne Pays; Martin R Pollak
Journal:  Science       Date:  2010-07-15       Impact factor: 47.728

4.  Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc.

Authors:  Fabian Bock; Khurrum Shahzad; Hongjie Wang; Stoyan Stoyanov; Juliane Wolter; Wei Dong; Pier Giuseppe Pelicci; Muhammed Kashif; Satish Ranjan; Simone Schmidt; Robert Ritzel; Vedat Schwenger; Klaus G Reymann; Charles T Esmon; Thati Madhusudhan; Peter P Nawroth; Berend Isermann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-24       Impact factor: 11.205

Review 5.  Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway.

Authors:  E A M Bouwens; F Stavenuiter; L O Mosnier
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

6.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

7.  APOL1 localization in normal kidney and nondiabetic kidney disease.

Authors:  Sethu M Madhavan; John F O'Toole; Martha Konieczkowski; Santhi Ganesan; Leslie A Bruggeman; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

8.  Low protein C and incidence of ischemic stroke and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Folsom; T Ohira; K Yamagishi; M Cushman
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

9.  Inflammation and coagulation markers and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Jade S Hiramoto; Ronit Katz; Carmen A Peralta; Joachim H Ix; Linda Fried; Mary Cushman; David Siscovick; Walter Palmas; Mark Sarnak; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2012-05-04       Impact factor: 8.860

10.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors:  Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal:  Hum Genet       Date:  2010-07-16       Impact factor: 4.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.